SCHEMBL4967657

SCHEMBL4967657

O=S1(=O)COc2ccc(-c3ccccc3)cc2N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.44
CA9 Q16790 2/20 0.44
KMT2A Q03164 5/20 0.44
KDM4E B2RXH2 4/20 0.44
MEN1 O00255 3/20 0.44
GAA P10253 2/20 0.44
MAPT P10636 4/20 0.41
NPC1 O15118 2/20 0.41
RXFP1 Q9HBX9 2/20 0.41
MAOA P21397 2/20 0.37
MAOB P27338 2/20 0.37
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
NR3C2 P08235 1/20 0.35
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PTGS2 P35354 1/20 0.35
PGR P06401 1/20 0.34
AKT1 P31749 1/20 0.34
AKT2 P31751 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4967297 0.78 KEAP1 (0.37) CA12CA9KMT2AKDM4EMEN1
SCHEMBL4967078 0.77 MMP12 (0.51) CA12CA9KMT2AKDM4EGAA
Hydrochloric Acid SCHEMBL8967934 0.76 KEAP1 (0.36) CA12CA9KMT2AKDM4EMEN1
SCHEMBL4987817 0.76 MEN1 (0.36) KMT2AMEN1GAAALDH1A1HPGD
SCHEMBL4964383 0.76 FABP6 (0.37) CA12CA9NR3C2PGR
SCHEMBL1333843 0.76 CA12 (0.40) CA12CA9MAPT
SCHEMBL3564650 0.72 PARP1 (0.37) CA12CA9GAANR3C2
SCHEMBL10208304 0.72 PARP1 (0.54) KMT2AKDM4EMEN1GAAMAPT
SCHEMBL8470138 0.71 KDM4E (0.52) CA12CA9KMT2AKDM4EMEN1
SCHEMBL304764 0.70 MAPT (0.62) KMT2AKDM4EGAAMAPTRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080171737-A1 CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-17 US disclosed
WO-2008073956-A2 CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171737-A1 CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 CA12 590/4885CA9 817/4885KMT2A 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.